ALKEM LABORATORIES Latest Share Price (ALKEM)
TODAY IN ONE LINE
ALKEM is little changed at ₹5190.00 on light volume — a quiet consolidation day.
With a market cap of ₹62,011.19 Cr., it trades at a P/E of 28.87. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ALKEM LABORATORIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Strong Return on EquityHealthy ROE of 16.4%
- ●Healthy Operating MarginsOPM is structurally strong at 20.6%
- ●Steady Dividend YieldReliable 1.02% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.11x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 22.7% YoY
- ●Sales ContractionQuarterly sales dropped 28.7% YoY
- ●Promoter SellingPromoter holding decreased by 1.50% QoQ
Latest ALKEM LABORATORIES News
What changed recently?
Recent events, corporate actions, and announcements.
ALKEM LABORATORIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ALKEM LABORATORIES, framed against the sector median so the premium or discount is obvious at a glance.
ALKEM LABORATORIES trades at a P/E of 28.87× and P/B of 4.51×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ALKEM LABORATORIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ALKEM LABORATORIES — derived from the latest tape, not yesterday's close.
ALKEM LABORATORIES last traded at ₹5,190 with an intraday range of ₹5,130–₹5,210.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹5190.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 5384.67 | +194.67 | +3.75% |
| R3 | 5304.17 | +114.17 | +2.20% |
| R2 | 5257.33 | +67.33 | +1.30% |
| R1 | 5223.67 | +33.67 | +0.65% |
| PIVOT | 5176.83 | -13.17 | -0.25% |
| CURRENT | 5190.00 | — | — |
| S1 | 5143.17 | -46.83 | -0.90% |
| S2 | 5096.33 | -93.67 | -1.80% |
| S3 | 5062.67 | -127.33 | -2.45% |
| S4 | 4982.17 | -207.83 | -4.00% |
ALKEM is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹5130–₹5210
Trading Inside opening range
ALKEM LABORATORIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ALKEM LABORATORIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
ALKEM LABORATORIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹62,011.19 Cr. and reported EPS of ₹47.67.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 12,965 | 14,712 ▲ 13.5% |
| Sales Growth YoY %Derived | 2.34% | 13.48% |
| Other Income | 494 | 583 ▲ 18.1% |
| Total Income | 13,458 | 15,296 ▲ 13.7% |
| 4,764 | 5,093 ▲ 6.9% | |
| Gross ProfitDerived | 8,200 | 9,620 ▲ 17.3% |
| Gross Margin %Derived | 63.25% | 65.38% |
| 5,688 | 6,614 ▲ 16.3% | |
| EBITDA (Operating Profit)Derived | 2,512 | 3,005 ▲ 19.6% |
| OPM %Derived | 19.38% | 20.43% |
| 479 | 368 ▼ 23.1% | |
| Profit Before Tax (PBT) | 2,527 | 2,871 ▲ 13.6% |
| 311 | 518 ▲ 66.5% | |
| Effective Tax %Derived | 12.31% | 18.03% |
| Total Profit for Period | 2,215 | 2,351 ▲ 6.1% |
| Less: Non-controlling Interests | 50 | 49 ▼ 1.1% |
| Net Profit (Owner's PAT)Derived | 2,165 | 2,302 ▲ 6.3% |
| Net Profit Margin %Derived | 16.70% | 15.65% |
| PAT Growth YoY %Derived | 20.59% | 6.30% |
| Earnings Per Share (EPS ₹) | 181.11 | 192.51 ▲ 6.3% |
| Diluted Shares Outstanding (Cr) | 12 | 12 ▲ 0.0% |
| Share of Profit from Associates/JVs | -1 | -2 ▼ 217.6% |
| Other Comprehensive Income (Net of Tax) | 20 | 184 ▲ 832.0% |
| Total Expenses (incl. D&A & Interest) | 10,931 | 12,425 ▲ 13.7% |
| Material Cost % of RevenueDerived | 26.54% | 24.23% |
| Employee Cost % of RevenueDerived | 18.93% | 19.28% |
| Other Cost % of RevenueDerived | 24.95% | 25.67% |
| Interest Coverage (x)Derived | 17.71x | 16.32x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 6,431 | 7,357 ▲ 14.4% | 8,344 ▲ 13.4% | 8,865 ▲ 6.2% | 10,634 ▲ 20.0% | 11,599 ▲ 9.1% | 12,668 ▲ 9.2% | 12,965 ▲ 2.3% | 14,712 ▲ 13.5% | |
| Sales Growth YoY %Derived | — | 14.40% | 13.42% | 6.24% | 19.96% | 9.08% | 9.21% | 2.34% | 13.48% | |
| Other Income | 96 | 88 ▼ 8.6% | 104 ▲ 18.8% | 233 ▲ 123.8% | 163 ▼ 30.3% | 216 ▲ 32.8% | 311 ▲ 43.9% | 494 ▲ 58.8% | 583 ▲ 18.1% | |
| Total Income | 6,527 | 7,445 ▲ 14.1% | 8,449 ▲ 13.5% | 9,098 ▲ 7.7% | 10,797 ▲ 18.7% | 11,815 ▲ 9.4% | 12,978 ▲ 9.8% | 13,458 ▲ 3.7% | 15,296 ▲ 13.7% | |
2,513 | 2,945 ▲ 17.2% | 3,345 ▲ 13.6% | 3,498 ▲ 4.6% | 4,180 ▲ 19.5% | 4,907 ▲ 17.4% | 4,938 ▲ 0.6% | 4,764 ▼ 3.5% | 5,093 ▲ 6.9% | ||
| Gross ProfitDerived | 3,918 | 4,412 ▲ 12.6% | 4,999 ▲ 13.3% | 5,367 ▲ 7.3% | 6,454 ▲ 20.3% | 6,692 ▲ 3.7% | 7,730 ▲ 15.5% | 8,200 ▲ 6.1% | 9,620 ▲ 17.3% | |
| Gross Margin %Derived | 60.93% | 59.97% | 59.91% | 60.54% | 60.69% | 57.70% | 61.02% | 63.25% | 65.38% | |
2,890 | 3,297 ▲ 14.1% | 3,526 ▲ 6.9% | 3,424 ▼ 2.9% | 4,401 ▲ 28.5% | 5,083 ▲ 15.5% | 5,485 ▲ 7.9% | 5,688 ▲ 3.7% | 6,614 ▲ 16.3% | ||
| EBITDA (Operating Profit)Derived | 1,028 | 1,115 ▲ 8.4% | 1,473 ▲ 32.2% | 1,942 ▲ 31.8% | 2,053 ▲ 5.7% | 1,609 ▼ 21.6% | 2,245 ▲ 39.5% | 2,512 ▲ 11.9% | 3,005 ▲ 19.6% | |
| OPM %Derived | 15.99% | 15.15% | 17.66% | 21.91% | 19.30% | 13.88% | 17.73% | 19.38% | 20.43% | |
198 | 248 ▲ 24.9% | 318 ▲ 28.3% | 334 ▲ 4.9% | 341 ▲ 2.4% | 315 ▼ 7.8% | 290 ▼ 7.8% | 479 ▲ 65.0% | 368 ▼ 23.1% | ||
| Profit Before Tax (PBT) | 926 | 955 ▲ 3.1% | 1,260 ▲ 32.0% | 1,842 ▲ 46.2% | 1,844 ▲ 0.1% | 1,305 ▼ 29.3% | 2,023 ▲ 55.1% | 2,527 ▲ 24.9% | 2,871 ▲ 13.6% | |
288 | 181 ▼ 37.0% | 110 ▼ 39.0% | 224 ▲ 103.1% | 164 ▼ 26.9% | 298 ▲ 81.7% | 212 ▼ 29.0% | 311 ▲ 46.9% | 518 ▲ 66.5% | ||
| Effective Tax %Derived | 31.05% | 18.96% | 8.77% | 12.18% | 8.89% | 22.84% | 10.46% | 12.31% | 18.03% | |
| Total Profit for Period | 638 | 774 ▲ 21.2% | 1,149 ▲ 48.6% | 1,618 ▲ 40.8% | 1,680 ▲ 3.9% | 1,007 ▼ 40.1% | 1,811 ▲ 79.9% | 2,215 ▲ 22.3% | 2,351 ▲ 6.1% | |
| Less: Non-controlling Interests | 7 | 13 ▲ 75.5% | 22 ▲ 69.4% | 33 ▲ 47.3% | 35 ▲ 6.0% | 23 ▼ 34.8% | 16 ▼ 30.7% | 50 ▲ 218.0% | 49 ▼ 1.1% | |
| Net Profit (Owner's PAT)Derived | 631 | 761 ▲ 20.5% | 1,127 ▲ 48.2% | 1,585 ▲ 40.6% | 1,646 ▲ 3.8% | 984 ▼ 40.2% | 1,796 ▲ 82.5% | 2,165 ▲ 20.6% | 2,302 ▲ 6.3% | |
| Net Profit Margin %Derived | 9.81% | 10.34% | 13.51% | 17.88% | 15.47% | 8.48% | 14.18% | 16.70% | 15.65% | |
| PAT Growth YoY %Derived | — | 20.54% | 48.20% | 40.63% | 3.82% | -40.19% | 82.47% | 20.59% | 6.30% | |
| Earnings Per Share (EPS ₹) | 52.77 | 63.61 ▲ 20.5% | 94.26 ▲ 48.2% | 132.57 ▲ 40.6% | 137.63 ▲ 3.8% | 82.31 ▼ 40.2% | 150.19 ▲ 82.5% | 181.11 ▲ 20.6% | 192.51 ▲ 6.3% | |
| Diluted Shares Outstanding (Cr) | 12 | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | 12 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | — | -1 | -2 ▼ 217.6% | |
| Other Comprehensive Income (Net of Tax) | -19 | 31 ▲ 263.5% | 27 ▼ 13.4% | -34 ▼ 227.7% | 34 ▲ 199.5% | 115 ▲ 236.6% | 20 ▼ 82.6% | 20 ▼ 1.6% | 184 ▲ 832.0% | |
| Total Expenses (incl. D&A & Interest) | 5,601 | 6,490 ▲ 15.9% | 7,189 ▲ 10.8% | 7,256 ▲ 0.9% | 8,953 ▲ 23.4% | 10,511 ▲ 17.4% | 10,955 ▲ 4.2% | 10,931 ▼ 0.2% | 12,425 ▲ 13.7% | |
| Material Cost % of RevenueDerived | 24.37% | 24.62% | 25.55% | 27.01% | 30.34% | 26.35% | 26.01% | 26.54% | 24.23% | |
| Employee Cost % of RevenueDerived | 18.53% | 18.52% | 18.04% | 18.29% | 18.46% | 18.37% | 17.38% | 18.93% | 19.28% | |
| Other Cost % of RevenueDerived | 26.41% | 26.30% | 24.21% | 20.34% | 22.93% | 25.45% | 25.92% | 24.95% | 25.67% | |
| Interest Coverage (x)Derived | 16.00x | 16.87x | 18.76x | 28.31x | 33.40x | 12.10x | 17.31x | 17.71x | 16.32x |
ALKEM LABORATORIES segment analysis : revenue and profit mix.
Disclosed business segments at ALKEM LABORATORIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
ALKEM LABORATORIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ALKEM LABORATORIES.
Our AI distills the core fundamental drivers supporting ALKEM LABORATORIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ALKEM LABORATORIES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Near-zero debt-to-equity 0.0011x provides fortress balance sheet and strategic flexibility.
Operating margin 20.61% reflects strong operational efficiency and competitive pricing power.
ROE 16.39% and ROCE 15.80% demonstrate solid capital efficiency near sector averages.
Operating cash flow ₹1,969.12 Cr covers capex with sustainable free cash flow generation.
Stable promoter holding 49.7% signals long-term commitment and governance alignment.
Key Risks.
Latest quarterly EPS declined 22.7% YoY despite revenue growth, signaling earnings compression.
High P/E 28.89x elevated relative to sector median, limiting margin of safety.
52-week price return 0% flat reflects market skepticism on earnings quality.
Dividend yield 0.38% low limits income appeal relative to peer pharmaceutical companies.
5-year revenue CAGR 6.1% flat growth versus sector 12–15% norm indicates stagnation.
Flip Conditions.
Valuation risk. a P/E above 38 (~0.9× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
ALKEM LABORATORIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ALKEM LABORATORIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ALKEM LABORATORIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ALKEM LABORATORIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ALKEM LABORATORIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ALKEM LABORATORIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ALKEM LABORATORIES stood at 54.6% of traded volume, against a 20-day average of 56.0%.
ALKEM LABORATORIES announcements: results, concalls, ratings, M&A.
Filings ALKEM LABORATORIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ALKEM LABORATORIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 245 documents below.
Shareholders meeting
Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure…
Analysts/Institutional Investor Meet/Con. Call Updates
Alkem Laboratories Limited has informed the Exchange about Q1 FY2027 - Earnings Conference Call Transcript
Shareholders meeting
Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s…
Copy of Newspaper Publication
Alkem Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Alkem Laboratories Limited has informed the Exchange about Link of Recording
Investor decks & rating reports.
ALKEM LABORATORIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ALKEM LABORATORIES has declared, sequenced by announce and record date.
ALKEM LABORATORIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ALKEM LABORATORIES: business, sector, key facts.
What ALKEM LABORATORIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ALKEM LABORATORIES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ALKEM, BSE: 539523.
Alkem Laboratories Limited is a multinational pharmaceutical company with a significant presence in India, the United States, and other international markets. Its core business revolves around the research, development, manufacturing, and sale of a diverse range of pharmaceutical and nutraceutical products. This broad portfolio allows them to cater to a wide spectrum of healthcare needs.
A major component of Alkem's business is the production and distribution of branded generic and generic drugs. These medications cover a wide range of therapeutic areas, including anti-infectives to combat infections, gastro-intestinal medications for digestive issues, pain relievers (analgesics), anti-diabetic treatments, drugs targeting the neuro/central nervous system, gynecological medications, respiratory treatments, dermatological products for skin conditions, and cardiac medications for heart health. This broad therapeutic reach underscores the company's commitment to comprehensive healthcare solutions.
Beyond branded and generic drugs, Alkem also manufactures and supplies active pharmaceutical ingredients (APIs). APIs are the fundamental building blocks of many medications, and their production represents a crucial aspect of the pharmaceutical supply chain. Alkem's involvement in API manufacturing strengthens its vertical integration within the industry and allows for greater control over the quality and supply of its finished products.
Furthermore, Alkem is venturing into the burgeoning biosimilars market. Biosimilars are similar to biologic drugs but are produced by different manufacturers, offering a potentially more affordable alternative. This expansion highlights Alkem's strategic focus on innovation and its commitment to providing cost-effective treatment options to patients.
Rounding out its offerings, Alkem produces and markets a range of nutraceuticals, which are products that provide health benefits beyond basic nutrition. This includes vitamins, minerals, and nutrients, as well as over-the-counter consumer products such as mouthwash, shampoos, pregnancy detection kits, and condoms. This diversification broadens their market reach and caters to a wider consumer base.
Established in 1973 and headquartered in Mumbai, India, Alkem Laboratories Limited has built a substantial presence in the global pharmaceutical landscape. Their multifaceted business strategy, encompassing a diverse range of products and therapeutic areas, positions them for continued growth and success in the competitive pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about ALKEM LABORATORIES (ALKEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ALKEM LABORATORIES (ALKEM)?
The current share price of ALKEM LABORATORIES (ALKEM) is ₹5,190.00. Today, the stock has declined by ₹3.00 (0.06%), trading in a range of ₹5,130.00 to ₹5,210.50. The stock opened at ₹5,190.00 with a trading volume of 63,261 shares.
02Is ALKEM LABORATORIES stock a good investment for long-term?
ALKEM LABORATORIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹62,011.19 Cr., P/E ratio of 28.87, ROE of 16.39%, and ROCE of 11.48%. The dividend yield stands at 1.02%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ALKEM LABORATORIES stock?
The 52-week high price of ALKEM LABORATORIES (ALKEM) is ₹5,933.50, while the 52-week low is ₹5,075.00. Currently trading at ₹5,190.00, the stock is 2.27% above its 52-week low and 12.53% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ALKEM LABORATORIES stock at the current price?
Whether to buy ALKEM LABORATORIES stock at ₹5,190.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.87 and P/B ratio of 4.51. Today's performance shows a loss of 0.06%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ALKEM LABORATORIES and when is the next dividend?
ALKEM LABORATORIES offers a dividend yield of 1.02%, which means for every ₹100 invested at the current price of ₹5,190.00, you can expect to receive approximately ₹1.02 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ALKEM LABORATORIES?
ALKEM LABORATORIES's key financial metrics include: P/E Ratio: 28.87, P/B Ratio: 4.51, ROE: 16.39%, ROCE: 11.48%, Dividend Yield: 1.02%, EPS: ₹47.67, Book Value: ₹1,200.09, and Debt-to-Equity: 0.11. The company's market cap stands at ₹62,011.19 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ALKEM LABORATORIES stock performing today in the market?
ALKEM LABORATORIES stock opened at ₹5,190.00 and is currently trading at ₹5,190.00, showing a decline of ₹3.00 (0.06%). The intraday high is ₹5,210.50 and low is ₹5,130.00. The trading volume stands at 63,261 shares, indicating moderate market participation today.
08What is the P/E ratio of ALKEM LABORATORIES and what does it indicate?
ALKEM LABORATORIES has a Price-to-Earnings (P/E) ratio of 28.87, which means investors are willing to pay 28.87 for every ₹1 of earnings. With an EPS of ₹47.67, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ALKEM LABORATORIES (ALKEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.